Radius Health, Inc.

Radius Health — Proxy Contest (July 2022)

33 slides from Radius Health's proxy contest presentation, Jul 7, 2022

  1. Slide 1: Actions To Date: Alignment to Shareholders

    Actions To Date: Alignment to Shareholders July 2022 1

  2. Slide 2: Table of Contents

    Table of Contents Executive Summary S E C T I O N 1 Radius Health Business S E C T I O N 2 Transaction Resulting from Strategic Assessment & Process S E C T I O N 3 Board & Corporate Governance S E C T I O N 4 Velan and Repertoire’s Proxy Fight is Misguided and Does Not Offer a Realistic Path for th

  3. Slide 3: Executive Summary

    Executive Summary Board has taken bold measures since 1H of 2020 to de-risk the business while maintaining / enhancing upside optionality for shareholders: • Replaced the previous long serving and original public company Chairman • Replaced the previous CEO and hired an externally sourced new CEO •

  4. Slide 4: Executive Summary (cont'd)

    Executive Summary (cont’d) • Experienced Board of Directors with domain expertise across all facets of the business (R&D, Clinical Development, Business Operations, Commercial Activities, CMC & Quality, Business Development and Finance) • Commitment to high standards of governance and continuous Boa

  5. Slide 5: Radius Health Business

    S E C T I O N 1 Radius Health Business 5

  6. Slide 6: Overview

    Overview • Global biopharmaceutical company: focus on bone health, oncology and neuro-endocrine/neuro-metabolic and behavioral • 2017, TYMLOS (abaloparatide) launch for the treatment of postmenopausal women with osteoporosis at high risk of fracture • $219 million TYMLOS product net revenue in FY202

  7. Slide 7: Progress Since First Half of 2020

    Progress Since First Half of 2020 Rebuilt the team 90% of the leadership team changed and 60% of current employees joined during that time period Created operating ~20% SG&A expense reduction (~$50 million) & total FTE headcount reduced ~ 31%, from ~375 to ~250 leverage Enhanced Increased net revenu

  8. Slide 8: Added Talent/Business Leaders

    Added Talent/Business Leaders JOINED IN APRIL 2020 JOINED IN MARCH 2022 Kelly Martin Mark Conley President and CEO Chief Financial Officer Kelly Martin is our President and Chief Executive Officer and joined the company in Mark serves as our Chief Financial Officer and joined the company in 2022. He

  9. Slide 9: Created Operating Leverage

    Created Operating Leverage QUARTERLY SG&A EXPENSES HEADCOUNT $36 376 $30 258 Q1 2020 Q1 2022 Q1 2020 Q1 2022 ~20% reduction in selling, general and Full-time headcount reduced by ~31%, from administrative (SG&A) expenses since Q1 2020 376 to 258 employees 9

  10. Slide 10: Enhanced Productivity per Commercial Employee

    Enhanced Productivity per Commercial Employee TYMLOS Net Revenue per Commercial Employee $374k $283k $225k Q1 2020 Q1 2021 Q1 2022 Productivity per commercial employee in Q1 2022 by 66% vs. Q1 2020 10

  11. Slide 11: Adjusted the Balance Sheet

    Adjusted the Balance Sheet • Partial refinancing of outstanding convertible notes, eliminating 2+ million shares of dilution risk and greatly improved flexibility in financing options for the company ($mm) $305 ~6.2mm in potentially ~3.9mm in potentially dilutive shares dilutive shares $193 $150 $10

  12. Slide 12: Despite operational improvements, stagnated share value growth

    Despite operational improvements, stagnated share value growth • Company lost ~70% of its market value due to a clinical failure in late 2021 • Signficant headwinds in the overall biotech marketplace for shareholders • Financial overhang with substantial debt limits opportunistic growth of company •

  13. Slide 13: Multi-Year Share Price Underperformance addressed by Board

    Multi-Year Share Price Underperformance addressed by Board 1 YEAR PRIOR TO TODAY (07/01/22) 3 YEARS PRIOR TO TODAY (07/01/22) 5 YEARS PRIOR TO TODAY (07/01/22) • Biotechnology 0% 20% 40% 10% companies offer 11.1% 20% (10%) 0% (26.4%) (13.3%) 18.0% appropriate (10%) 0% (20%) (42.6%) (0.8%) (20%) (44.

  14. Slide 14: Transaction Resulting from Strategic Assessment & Process

    S E C T I O N 2 Transaction Resulting from Strategic Assessment & Process 14

  15. Slide 15: Premium Transaction for Radius Shareholders

    Premium Transaction for Radius Shareholders Gurnet Point Capital and Patient Square Capital to acquire Radius for up to ~$890mm transaction value • 45% premium to 30-day volume-weighted average price of Radius stock (59% premium – inclusive of CVR payment) Compelling • Immediate upfront cash to Radi

  16. Slide 16: Transaction Overview

    Transaction Overview ▪ Up to ~$890mm transaction value, including the assumption of debt and assuming full payment of Transaction the CVR ▪ $10.00 per share in cash payable at closing, plus a $1.00 per share CVR Merger Consideration ▪ $1.00 per share CVR payable upon TYMLOS net sales reaching $300mm

  17. Slide 17: Premium to Radius Share Price and Value Post Abaloparatide-TD Failure

    Premium to Radius Share Price and Value Post Abaloparatide-TD Failure Transaction Premiums vs. Prior vs. 30-Day Consideration Trading Day VWAP $11.00 23.5% 59.4% $10.00 12.2% 44.9% 12/08/21: Announced results from Ph. 3 wearable trial where abaloparatide-TD did not demonstrate non-inferiority to TYM

  18. Slide 18: Radius Board Ran Robust and Thorough Strategic Process

    Radius Board Ran Robust and Thorough Strategic Process to Maximize Shareholder Value >70 Parties Engaged Over Course of Strategic Review, Across Multiple Opportunities WholeCo/TYMLOS M&A Other Strategic Processes • Transaction with Gurnet Point and Patient Square is Global Expansion the result of an

  19. Slide 19: Comprehensive Strategic Review Initiated by Board in 2020

    Comprehensive Strategic Review Initiated by Board in 2020 • Key Board of Directors considerations during strategic review process • Strengthening business • Enhancing shareholder value and reduce risk • Add to/diversify shareholder core value proposition of, predominantly abaloparatide-TD (“the patc

  20. Slide 20: Board & Corporate Governance

    S E C T I O N 3 Board & Corporate Governance 20

  21. Slide 21: Clear Commitment to High Standards of Governance

    Clear Commitment to High Standards of Governance BOARD & GOVERNANCE HIGHLIGHTS BOARD OVERVIEW Separate Chair and CEO Roles (1) Tenure Independence Ethnic Diversity Gender Majority voting standard for director elections, with resignation policy 3+ years Proposed elimination of supermajority voting pr

  22. Slide 22: Company Led and Overseen by a Refreshed and Diverse Board

    Company Led and Overseen by a Refreshed and Diverse Board William H. Dere Andrew C. von Eschenbach, M.D. Catherine J. Friedman Independent Director since November 2014 Independent Director since January 2021 Independent Director since August 2015 Age: 68 Age: 80 Age: 61 Audit Committee Nominating &

  23. Slide 23: Radius' Highly Qualified, Independent Director Nominees

    Radius’ Highly Qualified, Independent Director Nominees Catherine J. Friedman Jean-Pierre Garnier, Ph.D. Andrew C. von Eschenbach, M.D. Brings extensive experience as Brings significant business and Brings broad industry and a business executive with professional experience, regulatory experience se

  24. Slide 24: Radius Health's Board Has the Right Skills and Experiences

    Radius Health’s Board Has the Right Skills and Experiences SKILLS MATRIX & BOARD OVERVIEW DIRECTOR NOMINEE CONSIDERATIONS Biopharma / Life Sciences Industry Experience 100% • In considering whether to recommend candidates as Director nominees, the Nominating and Corporate Governance Committee will r

  25. Slide 25: Velan and Repertoire's Proxy Fight is Misguided

    S E C T I O N 4 Velan and Repertoire’s Proxy Fight is Misguided and Does Not Offer a Realistic Path for the Company 25

  26. Slide 26: Velan/Repertoire: Little Interest in Constructively Engaging with Radius

    Velan/Repertoire: Little Interest in Constructively Engaging with Radius Since the first engagement, and to date, Radius has attempted to constructively engage with Velan and Repertoire, including being open to their prior request to extending the director nomination deadline and interviewing their

  27. Slide 27: Velan and Repertoire Resorted to Misleading Editing of Statements

    Velan and Repertoire Resorted to Misleading and Disingenuous Editing of Statements RAD011 R&D Day 4Q 2020 Earnings Call Velan and “I spend…50% of my time on abaloparatide.” “...I joined the company [nine months ago], and I Repertoire can't explain the [TYMLOS patient growth during Misleading COVID]

  28. Slide 28: Velan and Repertoire Nominees are Not Additive

    Velan and Repertoire Nominees are Not Additive Eric Ende Cynthia Flowers Ann MacDougall Current public boards: Current public boards: Current public boards: NeuBase Therapeutics, Avadel G1 Therapeutics, Opiant Pharmaceuticals Pharmaceuticals, Matinas Biopharma Caladrius Biosciences, Hikma Holdings P

  29. Slide 29: Concluding Remarks

    S E C T I O N 5 Concluding Remarks 29

  30. Slide 30: Concluding Remarks

    Concluding Remarks Board has taken bold measures since 1H of 2020 to de-risk the business while maintaining / enhancing upside optionality for shareholders: • Replaced the previous long serving and original public company Chairman • Replaced the previous CEO and hired an externally sourced new CEO •

  31. Slide 31: Concluding Remarks (cont'd)

    Concluding Remarks (cont’d) • Experienced Board of Directors with domain expertise across all facets of the business (R&D, Clinical Development, Business Operations, Commercial Activities, CMC & Quality, Business Development and Finance) • Commitment to high standards of governance and continuous Bo

  32. Slide 32: Vote the BLUE Proxy Card Today

    Vote the BLUE Proxy Card Today The Radius Board of Directors unanimously recommends that you vote the BLUE proxy card “FOR ALL” of the Company’s highly qualified Board nominees 32

  33. Slide 33: Safe Harbor Cautionary Statement Regarding Forward-Looking Statements

    Safe Harbor Cautionary Statement Regarding Forward-Looking Statements This presentation includes forward-looking statements, including the ability of the parties to complete the transactions contemplated by the Agreement and Plan of Merger (the “Merger Agreement”) by and among Radius Health, Inc. (t

Radius Health — Proxy Contest (July 2022) on 6ix